215 related articles for article (PubMed ID: 17320115)
1. Optimal drug treatment regimens for HIV depend on adherence.
Krakovska O; Wahl LM
J Theor Biol; 2007 Jun; 246(3):499-509. PubMed ID: 17320115
[TBL] [Abstract][Full Text] [Related]
2. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients.
Turner BJ
J Infect Dis; 2002 May; 185 Suppl 2():S143-51. PubMed ID: 12001036
[TBL] [Abstract][Full Text] [Related]
3. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
4. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
5. Attaining higher goals in HIV treatment: the central importance of adherence.
Friedland GH; Williams A
AIDS; 1999 Sep; 13 Suppl 1():S61-72. PubMed ID: 10546786
[TBL] [Abstract][Full Text] [Related]
6. Emergence of HIV-1 drug resistance during antiretroviral treatment.
Rong L; Feng Z; Perelson AS
Bull Math Biol; 2007 Aug; 69(6):2027-60. PubMed ID: 17450401
[TBL] [Abstract][Full Text] [Related]
7. Drug-sparing regimens for HIV combination therapy: benefits predicted for "drug coasting".
Krakovska O; Wahl LM
Bull Math Biol; 2007 Nov; 69(8):2627-47. PubMed ID: 17578648
[TBL] [Abstract][Full Text] [Related]
8. Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
Llibre JM; Domingo P; del Pozo MA; Miralles C; Galindo MJ; Viciana I; Moreno S; Schapiro JM; Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):206-9. PubMed ID: 17999972
[TBL] [Abstract][Full Text] [Related]
9. Mutation and control of the human immunodeficiency virus.
Stengel RF
Math Biosci; 2008 Jun; 213(2):93-102. PubMed ID: 18439629
[TBL] [Abstract][Full Text] [Related]
10. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
[TBL] [Abstract][Full Text] [Related]
11. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
12. Simplifying antiretroviral therapy.
Tapper ML; Flexner C; Eron JJ; Molina JM
AIDS Read; 2004 Jul; 14(7):355-60, 367-71. PubMed ID: 15282865
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS.
Garvie PA; Lensing S; Rai SN
Pediatrics; 2007 Apr; 119(4):e893-9. PubMed ID: 17353298
[TBL] [Abstract][Full Text] [Related]
14. A model predictive control based scheduling method for HIV therapy.
Zurakowski R; Teel AR
J Theor Biol; 2006 Jan; 238(2):368-82. PubMed ID: 15993900
[TBL] [Abstract][Full Text] [Related]
15. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
16. [AIDS treatment in Africa: the risk of antiretroviral resistance].
Hamers RL; Schuurman R; van Vugt M; Derdelinckx I; Rinke de Wit TF
Ned Tijdschr Geneeskd; 2007 Dec; 151(48):2666-71. PubMed ID: 18179083
[TBL] [Abstract][Full Text] [Related]
17. Impact of once- and twice-daily dosing regimens on adherence and overall safety.
Hawkins T
AIDS Read; 2004 Jun; 14(6):320-2, 324, 329-31, 334-6. PubMed ID: 15243968
[TBL] [Abstract][Full Text] [Related]
18. Once-daily dosing of nevirapine in HAART.
Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
[TBL] [Abstract][Full Text] [Related]
19. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
Collazos J; Asensi V; Cartón JA
AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
[TBL] [Abstract][Full Text] [Related]
20. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
